Isolation of miRNA-rich extracellular vesicles for liquid biopsy
分离富含 miRNA 的细胞外囊泡用于液体活检
基本信息
- 批准号:10431224
- 负责人:
- 金额:$ 18.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibodiesAreaAttentionBiogenesisBiologicalBiological MarkersBlood CirculationBody FluidsCD81 geneCancer PatientCellsClinicClinicalCollaborationsColorectalColorectal CancerData SetDetectionDiseaseElectron MicroscopyEquipmentFlow CytometryFluorescenceGeneticGoalsHeterogeneityHumanKidneyKnowledgeLabelLaboratoriesLipidsMalignant neoplasm of ovaryMembrane ProteinsMethodologyMethodsMicroRNAsMicrofluidicsMicroscopyMusNormal CellNucleic AcidsOvarianPathway interactionsPatientsPlasmaPositioning AttributePrevalencePrognosisProteinsRNARecurrenceRenal carcinomaResolutionSiteStructureSurfaceTranslationsTumor-DerivedVesicleWorkXenograft Modelbasebiomarker developmentbody volumecancer biomarkerscancer cellcancer diagnosiscancer typeclinically relevantdetection sensitivityextracellular vesiclesinnovationinterestliquid biopsynanoparticlenovel strategiesoverexpressionpotential biomarkerprotein expressionresponsetumor
项目摘要
PROJECT SUMMARY/ABSTRACT
Extracellular vesicles (EVs) comprise a heterogeneous group of secreted membranous structures that contain a
variety of biomolecular cargo such as nucleic acids, proteins and lipids. EVs are ideal for liquid biopsy because
EVs are often more highly secreted by cancer cells than by normal cells, can be detected in body fluids of cancer
patients, and protect their cargo from degradation. Because EV cargo often reflects the genetic and biological
status of the cell of origin, constituents of EV cargo are promising biomarkers for cancer diagnosis, prognosis
and recurrence. Of these constituents, miRNAs have attracted substantial attention as potential biomarkers.
However, several studies indicate that a substantial proportion of EVs do not contain significant miRNA copy
numbers. These studies have implicated the existence of a subpopulation(s) of EVs that is enriched in miRNAs,
but this subpopulation has not been identified. The overarching goal of this study is to develop approaches to
isolate subpopulations of EVs that are enriched in miRNAs for liquid biopsy purposes. Our preliminary studies
have identified several distinct subpopulations of EVs based on their surface protein expression, and implicate
that the surface protein repertoire could identify EVs that are enriched in miRNAs. In this study, we will firstly
evaluate EVs that are secreted by human cancer cells and present in body fluids of patients with three major
types of cancers (ovarian, colorectal, renal) for the prevalence of EV subpopulations defined by their surface
protein repertoire. Secondly, we will determine the total miRNA content in each subpopulation of EVs that are
secreted by human cancer cells and present in cancer patient body fluids. Thirdly, we will evaluate the detection
of miRNAs in EVs that are isolated by immunocapture of different EV surface proteins from body fluids of tumor-
bearing mice and cancer patients. If successful, our study will provide answers to critical gaps-in-knowledge in
the EV biomarker field and, importantly, develop an approach for isolating miRNA-rich EVs that can be readily
used in a clinical laboratory setting for liquid biopsy purposes.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Honami Naora其他文献
Honami Naora的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Honami Naora', 18)}}的其他基金
Boosting anti-tumor immunity in the omentum for metastasis prevention
增强大网膜的抗肿瘤免疫力以预防转移
- 批准号:
10648192 - 财政年份:2023
- 资助金额:
$ 18.93万 - 项目类别:
Isolation of miRNA-rich extracellular vesicles for liquid biopsy
分离富含 miRNA 的细胞外囊泡用于液体活检
- 批准号:
10579299 - 财政年份:2022
- 资助金额:
$ 18.93万 - 项目类别:
Impact of diagnostic peritoneal lavage on omentum metastasis
诊断性腹腔灌洗对大网膜转移的影响
- 批准号:
10286303 - 财政年份:2021
- 资助金额:
$ 18.93万 - 项目类别:
Impact of diagnostic peritoneal lavage on omentum metastasis
诊断性腹腔灌洗对大网膜转移的影响
- 批准号:
10447751 - 财政年份:2021
- 资助金额:
$ 18.93万 - 项目类别:
Pre-metastatic Omental Niche Formation in Ovarian Cancer
卵巢癌转移前网膜微环境的形成
- 批准号:
10117199 - 财政年份:2018
- 资助金额:
$ 18.93万 - 项目类别:
Pre-metastatic Omental Niche Formation in Ovarian Cancer
卵巢癌转移前网膜微环境的形成
- 批准号:
10360586 - 财政年份:2018
- 资助金额:
$ 18.93万 - 项目类别:
Pre-metastatic Omental Niche Formation in Ovarian Cancer
卵巢癌转移前网膜微环境的形成
- 批准号:
9903259 - 财政年份:2018
- 资助金额:
$ 18.93万 - 项目类别:
Mechanism of evasion by ovarian cancers from anti-VEGF therapy
卵巢癌逃避抗 VEGF 治疗的机制
- 批准号:
9302312 - 财政年份:2016
- 资助金额:
$ 18.93万 - 项目类别:
Mechanism of evasion by ovarian cancers from anti-VEGF therapy
卵巢癌逃避抗 VEGF 治疗的机制
- 批准号:
9152040 - 财政年份:2016
- 资助金额:
$ 18.93万 - 项目类别:
Stromal Interactions and Leukemic Risk in Myelodysplastic Syndromes
骨髓增生异常综合征中的基质相互作用和白血病风险
- 批准号:
8897103 - 财政年份:2015
- 资助金额:
$ 18.93万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 18.93万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 18.93万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 18.93万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 18.93万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 18.93万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 18.93万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 18.93万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 18.93万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 18.93万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 18.93万 - 项目类别:














{{item.name}}会员




